An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 14, 2014

Primary Completion Date

May 23, 2016

Study Completion Date

May 23, 2016

Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
DRUG

Palovarotene

Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.

DRUG

Placebo

Trial Locations (4)

19104

University of Pennsylvania, Center for Research in FOP & Related Disorders, Philadelphia

94143

University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco

Unknown

Hôpital Necker-Enfants Malades, Department of Genetics, Paris

HA7 4LP

The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore

Sponsors
All Listed Sponsors
lead

Clementia Pharmaceuticals Inc.

INDUSTRY